Literature DB >> 2077263

[Tuberculosis sequelae: secondary fungal infections].

H Iwata1, T Miwa, K Takagi.   

Abstract

The antibody activities against Aspergillus fumigatus, Cryptococcus neoformans and Coccidioides immmitis by complement fixation (CF) were examined for active and cured pulmonary tuberculosis in 1985, and against Aspergillus fumigatus and Candida albicans by indirect hemagglutination (IHA) and counterimmunoelectrophoresis (CIE) in 1986. The antibody activity against Aspergillus by CF was positive in 8.6% of the sera and negative against Cryptococcus, and Coccidioides. The IHA results were positive in 2.9% against Aspergillus and in 44.9% against Candida. The CIE results were positive in 19.5% against Aspergillus and in 16.3% against Candida. Based on chest X-ray films, the development of pulmonary candidiasis was non-specific but that of pulmonary aspergilloma in tuberculous cavities was specific. Before aspergillomas were formed, the tuberculous cavities had become thin-walled. Then the cavities increased or decreased in size. It is postulated that the cavity has tension when check-valved by mycetome in the drainage bronchus, and becomes smaller or distinct when ventilated inadequately. In cases cavities do not change in size due to intracavitary proliferation of Aspergillus, the wall of cavity is rough, prominent, or opaque.

Entities:  

Mesh:

Year:  1990        PMID: 2077263

Source DB:  PubMed          Journal:  Kekkaku        ISSN: 0022-9776


  2 in total

1.  Prevalence of chronic pulmonary aspergillosis in patients with tuberculosis from Iran.

Authors:  M T Hedayati; Y Azimi; A Droudinia; B Mousavi; A Khalilian; N Hedayati; D W Denning
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-05-24       Impact factor: 3.267

2.  Prevalence of invasive aspergillosis in suspected pulmonary tuberculosis at a referral tuberculosis hospital in Shandong, China.

Authors:  Jun-Li Wang; Xiao-Lin Zhou; Chao Han; Mao-Shui Wang; Hua Hu
Journal:  Epidemiol Infect       Date:  2020-11-05       Impact factor: 2.451

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.